Biotechnology

REMEGEN

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

REMEGEN released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue HKD 743.98 M, actual EPS HKD 0.6575

Rongchang Biotech Unveils Global First-in-Class PR-ADCs Platform at AACR and Reports Strong Performance

REMEGEN FY2026 Q1 Earnings Release Scheduled for April 28 After-Market BJT

Rongchang Biotechnology and AbbVie Sign Exclusive Licensing Agreement for RC148 and Receive Upfront Payment

Rongchang Biopharmaceutical's Drug Receives Approval for Cancer Indication

Rongchang Biotech's Vensedotin New Indication Approved

CICC Raises Forecast for Rongchang Biotech's 2026 Net Profit and Target Price

Rongchang Biotech Announces Profitable 2025 Annual Report

Rongchang Biotechnology's RC288 Receives NMPA Approval for Clinical Trials

Rongchang Biotechnology Reports Profit of 710 Million Yuan for 2025 Year

Rongchang Biotech Announces 2025 Annual Report, Reversing Loss to Profit

Rongchang Biotechnology's Veseplimab Receives New Indication Approval

REMEGEN to Release FY2025 Earnings on March 27 Pre-Market (BJT), Forecast Revenue HKD 3.316 B, EPS HKD -0.4063

Rongchang Biotech to Hold Board Meeting to Approve Annual Results and Consider Dividend Payment

Rongchang Biotechnology Expected to Turn Profit in 2025

Nomura Predicts Robust Revenue and Profit Growth for RemeGen

Rongchang Bio achieved RMB 325,105.11 million in revenue in 2025, up 89.36%, with a net profit of RMB 70,852.33 million

REMEGEN released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue HKD 3.553 B (forecast HKD 3.316 B), actual EPS HKD 1.4099 (forecast HKD -0.4041)

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

09995

688331

159849

516500

520690

159837

512290

159992

512010

159316

510660

159506

520880

513120

513700

159615

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

Tip Ranks

RemeGen

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

China Southern Hang Seng Biotech ETF(QDII)

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

RemeGen Co. Ltd. has approved a cash management plan to invest up to RMB2.5 billion of idle funds in wealth management products. Recently, the company entered agreements with HTSC to invest RMB453 million in low-to-medium risk, fixed-income products, which may enhance interest income and demonstrate prudent treasury management. This transaction is disclosed under Hong Kong listing rules. The latest analyst rating for RemeGen (HK:9995) is a Buy, with a price target of HK$129.00.

HTSC

Huatai Securities Co., Ltd. GDR Class A RegS

RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products

01877

688180

Hong Kong's biotechnology sector is facing a downturn, with notable declines in key stocks. Akeso Inc.dropped over 9%, Rongchang Biopharmafell more than 4%, and Junshi Biosciencesdecreased by over 3%. This market volatility has negatively affected investor sentiment in the biotech industry.

CoinLive

JUNSHI BIO

Junshi Biosciences

AKESO

Hong Kong Biotech Stocks Decline Amid Market Volatility

RemeGen (SEHK:9995) reported Q1 2026 revenue of C¥656.2 million and a profit of C¥328 million, marking a significant turnaround from previous losses. The company achieved a trailing twelve-month net income of ¥1.3 billion, with EPS rising to ¥2.33. Despite a positive outlook with revenue growth projected at 14.9% annually, concerns about non-cash earnings persist. RemeGen's shares trade at HK$100.10, with a P/E of 37.8x, below the DCF fair value of HK$114.32. Investors are advised to consider the long-term trends and earnings quality before making decisions.

Simplywall

RemeGen Q1 Profit Of ¥328m Revives Bullish Narratives On Biotech Turnaround

300765

China's pharmaceutical industry is rapidly evolving, with major companies like CSPC Pharmaceutical and RemeGen securing significant out-licensing agreements. The shift from low-cost manufacturing to high-value innovation is evident, particularly with the integration of AI in drug discovery. AI is compressing preclinical timelines and enhancing R&D capabilities. China now accounts for 30% of the global experimental drug pipeline and is a leader in antibody-drug conjugate projects. This growth has raised concerns among US lawmakers about China's potential dominance in the global pharmaceutical supply chain.

SCMP

CSPC Innovation

China’s drug makers are speeding up – will AI be their secret weapon?

02442

06651

09606

02575

02225

02657

00290

02509

01530

EASY SMART GP(02442) rose 21.49%, with a trading turnover 53.3 Million HKD, and a year-to-date rose 109.8%. 51WORLD(06651) rose 15.21%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 37.8%. DUALITYBIO-B(09606) rose 10.81%, with a trading turnover 488.5 Million HKD, and a year-to-date rose 6.6%.

Top Gainers&Losers

EASY SMART GP

51WORLD

DUALITYBIO-B

XUANZHUBIO-B

JINHAI MED TECH

FOREST CABIN

GOFINTECH QUANT

QYUNS-B

3SBIO

Top 10 HK Stock Gainers (4.15)

Hong Kong stocks closed higher on April 15, 2026, with the Hang Seng Index up 0.29% at 25,947.32 points and the Hang Seng Tech Index rising 1.23% to 4,911.79 points. The total market turnover was 245.588 billion Hong Kong dollars. The innovative drug sector saw significant gains, while shale gas and Foxconn stocks declined. Notable gainers included Xuanzhu Biopharmaceuticals-B (+10.5%) and Rongchang Biopharmaceuticals (+9%). Conversely, Zhihu and Xunlei fell by 8.5%.

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hang Seng Index

Hang Seng TECH Index

LAOPU GOLD

JD-SW

JD.com

BABA-W

Alibaba

JD HEALTH

TRIP.COM-S

BIDU-SW

Baidu

Zhihu

Xunlei

NEW ORIENTAL-S

New Oriental EDU & Tech

TIANQI LITHIUM

GANFENGLITHIUM

Ganfeng Lithium

LI NING

Sunshine Guojian Pharmaceutical

Laopu Gld HK SDR 50to1

JD-SWR

BABA-WR

Alibaba HK SDR 5to1

JD HEALTH-R

Trip.com HK SDR 50to1

Trip.com

BIDU-SWR

ZHIHU-W

LI NING-R

STOCKS | Hong Kong Stocks Close Higher with Tech Sector Leading Gains

RemeGen Co. Ltd. has received approval from China's National Medical Products Administration for its antibody-drug conjugate Disitamab Vedotin, in combination with Toripalimab, as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. This marks the drug's fifth approved indication in China, supported by a Phase III trial demonstrating improved survival rates over traditional chemotherapy. The approval enhances RemeGen's position in the oncology market and expands treatment options for patients. Analysts rate RemeGen's stock (HK:9995) as a Buy with a price target of HK$124.00.

RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer

02513

02526

03636

09887

09880

06600

09966

06636

KNOWLEDGE ATLAS(02513) rose 31.94%, with a trading turnover 5.0 Billion HKD, and a year-to-date rose 687.4%. EASY SMART GP(02442) rose 31.13%, with a trading turnover 32.0 Million HKD, and a year-to-date rose 91.4%. DIAGENS-B(02526) rose 24.34%, with a trading turnover 161.2 Million HKD, and a year-to-date rose 148.7%.

REMEGEN(09995.HK)